179 search results for: Pathophysiology

Pathophysiology of Bullous Pemphigoid
Dermatology
Pathophysiology of Bullous Pemphigoid
expert video

Join Dr. Schmidt as he describes the pathophysiology of bullous pemphigoid, as well as novel research avenues to better understand this complicated disease.

View more
Pathophysiology of Blister Formation in Bullous Pemphigoid
Dermatology
Pathophysiology of Blister Formation in Bullous Pemphigoid
expert video

Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation

View more
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
Dermatology
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
expert video

Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively. 

View more
Complex EoE <b>Pathophysiology</b> Beyond Esophageal Eosinophilia
Gastroenterology
Complex EoE Pathophysiology Beyond Esophageal Eosinophilia
expert video

Dr. Jonathan Spergel and Prof. Arjan Bredenoord highlight the importance of different immune cells in type 2 inflammation in EoE.

View more
The <b>Pathophysiology</b> of Prurigo Nodularis
Dermatology
The Pathophysiology of Prurigo Nodularis
videoanimation

An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

View more
The Role of IL-4 and IL-13 in the <b>Pathophysiology</b> of CSU
Dermatology
The Role of IL-4 and IL-13 in the Pathophysiology of CSU
expert video

Dr. Jason Hawkes details the role of IL-4 and IL-13 in the pathophysiology of CSU at EADV 2025

View more
Epidemiology and <b>Pathophysiology</b> of AD in Children
Dermatology
Epidemiology and Pathophysiology of AD in Children
expert video

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease

View more
Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE
Gastroenterology
Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE
expert video

Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

View more
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in BP
Dermatology
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)
expert video

In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.

View more
Understanding IL-33: A Key Factor in COPD Pathogenesis
Pulmonology
Understanding IL-33: A Key Factor in COPD Pathogenesis
interactivity

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.

View more
Barrier Breakdown: The Role of Type 2 Inflammation in AD and Atopic Sensitization
Dermatology
Barrier Breakdown: The Role of Type 2 Inflammation in AD and Atopic Sensitization
expert video

Dr. Jeff Yu presents the clinical presentation of pediatric AD and highlights how type 2 inflammation contributes to symptoms and development of atopic comorbidities such as food allergy and asthma at PeDRA 2025

View more
The Growing Burden: Cumulative Disease Impact and Comorbidities in Pediatric AD
Dermatology
The Growing Burden: Cumulative Disease Impact and Comorbidities in Pediatric AD
expert video

Dr. Yu and Dr. Wine Lee discuss the clinical presentation and burden of atopic dermatitis, the role of type 2 inflammation in the development of atopic comorbidities, and the importance of early intervention in potentially preventing cumulative life course impairment in AD at PeDRA 2025.

View more